In one paragraphArticle in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Nia ChoiSchool of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Saira KhaderiSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Sumeet K AsraniBaylor University Medical Center, Dallas, Texas, USA.
Michelle LusterSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Abeer Al-SarrajSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Jinyoung ByunDivision of Epidemiology, Biostatistics, and Preventive Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.ORCID https://orcid.org/0000-0001-8579-1435 Christopher I AmosDivision of Epidemiology, Biostatistics, and Preventive Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.ORCID https://orcid.org/0000-0002-8540-7023 Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MTissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3MTranslational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Casey W Wright · 2019 to 2026
$14.7MPrevention of Hepatocellular Carcinoma Related to Metabolic SyndromeP01CA263025 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2022 to 2026
$8.9MRisk Stratification for and Early Detection of Liver CancerU01CA230997 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jagpreet Chhatwal, Hashem B El-Serag · 2018 to 2026
$6.4MClinical Validation Center for Hepatocellular CarcinomaU01CA271887 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI FASIHA KANWAL, JORGE A MARRERO · 2022 to 2026
$4.7MGenome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)R01CA186566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I., HASSAN, MANAL METWALLY · 2015 to 2019
$3.6MMulti-level Evaluation of Racial/ethnic Disparities in Liver Disease OutcomesR01CA256977 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KANWAL, FASIHA, SINGAL, AMIT · 2021 to 2025
$3.0MGenetic Epidemiology of Hepatocellular Carcinoma in African AmericansR01CA274528 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Aaron Peter Thrift · 2023 to 2026
$1.4MEvaluating Etiological Impact of Metatranscriptomic and Immunological Features for Lung CancerR03CA262911 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LIU, YANHONG · 2021 to 2022
$160kCancer Prevention and Research Institute of Texas RP150587Cancer Prevention and Research Institute of Texas RP190641Cancer Prevention and Research Institute of Texas RP200537Cancer Prevention and Research Institute of Texas RP200554Cancer Prevention and Research Institute of Texas RP220119Cancer Prevention and Research Institute of Texas RP250355Center for Innovations in Quality, Effectiveness and Safety CIN 13-413NCI NIH HHS P01 CA263025NCI NIH HHS P01 CA263025-03S1NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA186566NCI NIH HHS R01 CA256977NCI NIH HHS R01 CA274528NCI NIH HHS R03 CA262911NCI NIH HHS U01 CA230997NCI NIH HHS U01 CA271887NIDDK NIH HHS P30 DK056338NIDDK NIH HHS P30 DK 56338NIEHS NIH HHS P30 ES030285NIEHS NIH HHS P30ES030285
6 · The paper itselfAbstract
BACKGROUND AND
aimsGenome-wide association studies (GWAS) that were previously conducted in European and Asian cohorts have identified numerous genetic risk factors for hepatocellular carcinoma (HCC) and its precursors and risk factors. A polygenic risk score (PRS) composed of these key SNPs for HCC may be useful for risk stratification in clinical settings for U.S. patients with cirrhosis.
methodsUsing genetic and clinical data from the Texas HCC Consortium cohort, we evaluated a weighted PRS constructed from 11 independent SNPs previously shown to be associated with advanced liver disease (PNPLA3-TM6SF2-GCKR-HSD17B13-GATAD2A-TRIB2-PPP1R3B-CPN1-ERLIN1-APOE-MBOAT7). We used Fine-Gray competing risk models to estimate hazard ratios (HR) and 95% confidence intervals (CI) to test the association between the PRS and HCC.
resultsThe 1888 patient cohort included non-Hispanic White (NHW; 50.4%), non-Hispanic Black (NHB; 18.5%), and Hispanic (28.6%) patients, and 116 developed incident HCC. Each unit increase in the PRS was associated with increasing risk of HCC (HR = 2.20; 95% CI (1.53, 3.18)). The 11-SNP PRS was strongly associated with risk of HCC in NHW patients (HR = 2.53, 95% CI (1.65, 3.89)) but not among NHB and Hispanic patients. Similarly, the magnitude of the PRS effect on HCC risk differed by cirrhosis etiology with the strongest association for cirrhosis due to Hepatitis C (HR = 3.81, 95% CI (1.64, 8.82)).
conclusionsOur study shows that PRS is generally promising for HCC risk prediction; however, the current PRS that was derived from previous GWAS of primarily NHW and Asian patients is not robust over different groups, limiting their use for risk stratification in diverse populations with different etiologies.
Indexed as
Carcinoma, HepatocellularEthnicityLiver CirrhosisLiver NeoplasmsAgedFemaleGenetic Predisposition to DiseaseGenetic Risk ScoreGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideRisk AssessmentRisk FactorsTexasancestry‐specific variantsgenetic epidemiologyliver cancerrisk stratification
Identifiers
PMID42851002
PMCPMC13650403
What OpenQuestion holds
Textmetadata
Read underepoch 390